Literature DB >> 9837788

A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions.

J E Johnson1, W Rodgers, J K Rose.   

Abstract

Previous studies showed that the HIV-1 envelope (Env) protein was not incorporated into vesicular stomatitis virus (VSV) virions unless its cytoplasmic tail was replaced with that of the VSV glycoprotein (G). To determine whether the G tail provided a positive incorporation signal for Env, or if sequences in the Env tail prevented incorporation, we generated mutants of Env with its 150-amino-acid tail shortened to 29, 10, or 3 amino acids (Envtr mutants). Cells infected with VSV recombinants expressing these proteins or an Env-G tail hybrid showed similar amounts of Env protein at the surface. The Env-G tail hybrid or the Envtr3 mutant were incorporated at the highest levels into budding VSV virions. In contrast, the Envtr29 or Envtr10 mutants were incorporated poorly. These results defined a signal preventing incorporation within the 10 membrane-proximal amino acids of the Env tail. Confocal microscopy revealed that this signal functioned by causing localization of human immunodeficiency virus type 1 Env to plasma membrane domains distinct from the VSV budding sites, where VSV proteins were concentrated. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837788     DOI: 10.1006/viro.1998.9429

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Vesicular stomatitis virus-simian retrovirus type 2 vaccine protects macaques from detectable infection and B-cell destruction.

Authors:  Rajeev Gautam; Arun Iyer; Meredith Hunter; Arpita Das; Tessa Williams; Jason Dufour; Cristian Apetrei; K Gus Kousoulas; Preston A Marx
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

5.  Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.

Authors:  Yanhua Gao; Patricia Whitaker-Dowling; Simon C Watkins; Judith A Griffin; Ira Bergman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway.

Authors:  E Boritz; J Gerlach; J E Johnson; J K Rose
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.

Authors:  Michael A Whitt
Journal:  J Virol Methods       Date:  2010-08-13       Impact factor: 2.014

8.  Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Infectious Entry Pathway Mediated by the Human Endogenous Retrovirus K Envelope Protein.

Authors:  Lindsey R Robinson; Sean P J Whelan
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

10.  Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome.

Authors:  Mauricio A Martins; Lucas Gonzalez-Nieto; Michael J Ricciardi; Varian K Bailey; Christine M Dang; Georg F Bischof; Nuria Pedreño-Lopez; Matthias G Pauthner; Dennis R Burton; Christopher L Parks; Patricia Earl; Bernard Moss; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.